For high risk prostate cancer, the treatment volumes and even dose levels are still a controversial issue. The aim of this study is to evaluate the dosemetric parameters and acute toxicity of dose-escalated whole pelvis (WP) Intensity Modulated Radiation Therapy (IMRT) and volumetric modulated arc therapy (VMAT) prostate boost following neoadjuvant and concomitant with androgen deprivation therapy in high-risk prostate cancer patients. This analysis included 73 high-risk prostate cancer patients treated with WP-IMRT followed by boost to the prostate by VMAT to total dose of 80 Gy; between January 2014 and October 2016. Androgen deprivation therapy (ADT) was given for all patients before and during radiation therapy. Drawing the dose volume histograms (DVHs) was done for planning target volumes (PTVs), including Prostate PTV & nodal PTV, and organs at risk including rectum, bladder, femoral heads, and bowel bag for the plans. Acute radiation toxicities were reported during the radiation course and the following 3 months. The DVH analysis showed good coverage of PTVs and organs at risk doses were acceptable. No recorded acute Grade ≥ 3 toxicity. Acute grade 1 toxicity for Gastrointestinal (GI) and Genitourinary (GU) were 65% and 35% respectively, while Grade 2 toxicity was 30% for both. The Proctitis and frequency were the commonest acute toxicity and were maximal during the 5th week of radiation therapy. Dose escalation in two phases utilizing Simultaneous integrated boost (SIB) combined with ADT in high risk prostate cancer patient is feasible and associated with acceptable acute GI and GU toxicity. How to cite this paper: Daoud, M.A., Saleh, Y.M., Elsherbini, M. and Al Etreby, M. (2019) Evaluation of Acute Toxicity and Dosimetric Parameters in High Risk Prostate Cancer Patients Treated by High Radiation Doses. Journal of Cancer Therapy, 10, 654-670.
Introduction
Dose-escalated radiation therapies (80 Gy and higher) in high-risk prostate cancer patients have demonstrated improvement in outcome and biochemical disease-free survival [1] [2] [3] . In a Phase III trial, The Radiation Therapy Oncology Group (RTOG) showed improved progression-free survival (PFS) for high-risk prostate cancer patients treated with Whole Pelvis Radiation Therapy (WPRT) compared with prostate-only radiation therapy (PORT) [4] . Also, an updated analysis of the same study demonstrated improvement of PSA control and PFS at 10 years with added neoadjuvant hormonal therapy to WPRT [5] .
Hence, there is increased interest in radiation dose escalation combined with androgen deprivation in high risk prostate cancer patients [6] [7] . An ongoing GETUG-AFU-18 phase III trial is evaluating the impact of dose escalation in combination with 3-year androgen deprivation treatment on 5-year biochemical or clinical control in high-risk prostate cancer patients [8] . Dose escalation can be achieved with either 3-Dimensional Conformal Radiation Therapy or with intensity-modulated Radiation Therapy (IMRT). Previous studies demonstrated the superiority of IMRT over the conventional radiation techniques for WPRT in sparing of organs at risk [9] and superior target coverage [10] . In an analysis using SEER data showed that patients treated with IMRT were less likely to have physician reported gastrointestinal morbidity compared to those treated with 3-DCRT but more likely to have erectile dysfunction [11] . Furthermore, recent clinical trials confirmed that WP-IMRT had acceptable rates of acute toxicity [12] [13] [14] . IMRT permits the use of different total doses and different doses/fraction to different volumes within the irradiation field, utilizing the "simultaneous integrated boost" (SIB) technique. Consequently, the IMRT-SIB technique allows different doses to the prostatic area and the pelvic lymph nodes. However, in the context of dose escalation to the prostate, dosimetric and clinical results from the literature comparing WP IMRT with PO IMRT are still limited. In a planning study, Guckenberger demonstrated similar toxicity risks for rectum, bladder and small bowel in both WP IMRT and PO IMRT [15] . Volumetric Modulated Arc Therapy (VMAT) Provides excellent dose distribution with less treatment time and monitor units. Planning studies on dosimetric comparison of the prostate only demonstrated that VMAT provided equal or better target coverage and normal tissue sparing over IMRT [16] [17] [18] .
The aim of current study is to assess the dosimetric parameters and acute toxicity of dose-escalated WP-IMRT and VMAT prostate boost combined with neoadjuvant and concurrent androgen deprivation therapy in high risk patients of prostate cancer.
Materials and Methods

Patients
The study included a cohort of 73 high-risk prostate cancer patients treated in two hospitals with WP-IMRT followed by prostate boost by VMAT to total dose of 80 Gy between January 2014 and October 2016. All patients had locally advanced disease with no distant metastasis and not suffering from other malignant disease. In this analysis, we aimed at evaluation of the dosimetric parameters for the dose escalation and its impact on the acute toxicity when combined with androgen deprivation therapy. Recording the grades of acute toxicity for this combined treatment modality was our primary outcome. All patients were diagnosed by trans-rectal ultrasound-guided core biopsy, 12 cores were obtained for each patient. High-risk was defined as cT3/4 N0 M0, according to the 2010 American Joint Committee on Cancer staging classification [19] , and/or a Gleason score of ≥8 and/or a pretreatment PSA concentration of ≥20 ng/ml. The local institutional ethics committee of Fakeeh Hospital approved the study. Patient characteristics are shown in Table 1 . All patients received androgen deprivation therapy (ADT), starting 4 -6 months before Radiation Therapy (RT) and continued for a total period of ≥24 months. was contoured from the level of the ischial tuberosities to the recto-sigmoid flexure, and the whole bladder was contoured from its apex to the dome. Both femoral heads were delineated to the level of the ischial tuberosities. The bowel bag was contoured as the entire volume of peritoneal space down to level of S1. The treatment plan was given in two phases. In the first phase, the nodal PTV and the prostate PTV received 48.6 Gy and 54 Gy, respectively, both in 27 fractions. IMRT with a simultaneous integrated boost (SIB) technique was selected in phase one treatment. Nine co-planner fields are aligned equal-spaced in 360• around the patient (0, 40, 80, 120, 160, 200, 240, 280, and 320). Planning risk volumes PRVs were created for rectum and bladder to exclude from the high dose region. Other helping contours (Ring structures with 0.3 cm internal margin and 3 cm external margin) were created around the nodal and prostate PTVs separately for better control the dose fall off beyond each PTV. A set of dose constrains were defined for the PTVs and the OARs, and no normalization method was selected for any IMRT plan. Two lower limits were defined for each PTV as 100% and 97% of the volume and prescribed to 95% and 100% of the Journal of Cancer Therapy dose; also two upper limits, 2% and 0.1% of the volume were defined as 101% and 103% of the prescribed dose respectively. By using these constrains and through the interactive optimization process, the mean and median dose for each PTV is usually kept equal to the corresponding prescribed dose. Smoothing Objectives were also used to have smoother fluence in the x-direction to ensure minimal MU factor. In the second phase, the prostate PTV received 26 Gy in 13 fractions using double-arc VMAT clock wise and counter clockwise (CW & CCW). Control points for each arc were adjusted to give at least 1.5 angle step resulting in 178 control points. Variable collimator angle was defined for each arc to minimize the tongue and groove effect. Both phases were optimized using photon optimization algorithm (PO) newly developed in Eclipse V16.0.03. Treatment Plans were considered acceptable when ≥ 95% of the PTV received ≥ 95% of the prescribed dose. For the OAR dose volume constraints were: Rectal mean dose less than 50 Gy, minimal dose of 70 Gy (V70Gy) less than 15% and V50Gy less than 45%; and V70Gy less than 25% and V50Gy less than 50% for the bladder. For the femoral heads, the maximal point dose was less than 55 Gy and minimal dose to 2% (D2%) less than 50 Gy. For the bowel bag, V45Gy was less than 195 ml. The dose calculation was performed using the anisotropic analytic algorithm (AAA, version 16.0.03) and a voxel size of 0.25 × 0.25 × 0.25 cm 3 .
Simulation Organ Contouring and Planning
Image Guidance
Online image-guided radiotherapy, patients were treated with a Traiology treatment unit (Varian Medical Systems, USA). Daily KV image guidance with On Board Imaging (OBI) and bi-weekly cone beam CT (CBCT) was performed in all patients. In the initial set up, the patients were immobilized in Headrest, kneefix and feetfix; the skin marks on the patient were used after applying shift. Orthogonal kilovoltage radiographs of the patients were then obtained using the OBI and registered to the reference digitally reconstructed radiographs (DRR) generated from the planning CT. Once the bone registration was well adjusted, CBCT images were also performed and used to obtain the target/soft tissue registration.
Dosimetric Analysis
Dose-volume histograms (DVHs) were constructed for the prostate PTV, nodal PTV, rectum, bladder, femoral heads, and bowel bag in each plan. Parameters chosen for measuring dosimetric quality of treatments were D95% and D2% for the prostate PTV and for nodal PTV were mean dose and D95%. For the rectum and bladder, the analysis included the (Maximum Dose) D max, mean dose, V75Gy, V70Gy, V65Gy and V50Gy. For the bowel bag and femoral heads V45Gy and D max were measured respectively.
Acute Radiation Toxicity
All patients were checked weekly during radiation therapy and two weeks following radiation then monthly thereafter. Acute toxicity is reported during radiation and in the first 3 months following treatment using the Common Termi- 
Statistical Analysis
An unpaired Student's t test was used to compare mean values of each dosimetric parameter. Chi-square analysis was used for toxicity profile analysis. All statistical analyses were performed using the software SPSS version 22.0 (SPSS Inc., Chicago, IL, USA). All reported P-values are two-tailed and P < 0.05 was considered statistically significant.
Results
All Patients received the prescribed dose with no interruption of treatment due to acute radiation toxicity. Androgen deprivation therapy (ADT) was given for all patients before and during radiation therapy. Seven patients continued their ADT post radiation to complete 24 months. The dose distribution in both axial and coronal plans for one patient is shown in Figure 1 . The dosimetric values for the PTVs and Organs at risk (OAR) are illustrated in Table 2 . All the increased gradually with progress of radiation therapy weeks. In Figure 3 and Figure 4 the frequency increased in incidence and grade and became maximum (Grade 2) during the 5th week and continued till 8th week of radiation therapy. Acute diarrhea reached its maximum prevalence during the 5th week then decreased after that due to the end of whole pelvic irradiation. When the Grade of toxicity ≤1, Grade 2 was compared in correlation with the different dose levels to the rectum, bladder and bowel bag (Table 4 ). There was no significant correlation with any dose level and the grade of toxicity.
Discussion
In patients with high-risk prostate cancer treatment volumes and even dose levels are still controversial issue [22] . Some investigators showed no difference between PORT and WPRT [23] . However, a major limitation of their study was the relatively small dose delivered of 72 Gy. A large phase III trial (RTOG 0924)
is ongoing to answer the question of survival benefit of dose escalation WPRT combined with ADT in high risk patients [24] . Whole pelvic irradiation is often recommended in this setting, raising concerns about an increase in radiation toxicity to the organs at risk. The new technical developments such as SIB-IMRT, VMAT combined with IGRT have allowed radiation oncologists to achieve a better protection of risk organs while providing higher dose conformity to target volumes. In our study, all patients received ADT and dose escalation was done through 2 phases while maintaining the standard dose fractionation rang (1.8 -2 Gy) in order to obtain the highest possible cell killing effects. Dose escalation can be obtained in single phase by SIB to WPLNs with hypofractionation regimen to the prostate. However, the efficacy and late toxicity of this regimen still need investigations [25] . Furthermore, despite the total dose to the pelvis (50 -52 Gy) with α/β 1.5 Gy, it is unlikely to eradicate subclinical or detectable LNs metastases that could have a different radiobiological behavior from the primary lesion, being more aggressive and showing a more cellular replication and metastatic potential. Based on this hypothesis, the α/β ratio to be taken in consideration for LN metastases is likely to be 1.8 -2 Gy. We chose the SIB-IMRT in phase I for the pelvic LNs and the prostate as this technique generated concave dose distributions and delivered radical doses to the pelvic nodes and prostate gland while reducing the dose to surrounding organs at risk. The same finding was reported before by Yoo et al. [26] in a dosimetric study comparing the treatment plans of ten patients with PTV including prostate, seminal vesicles, and lymph nodes. They showed that IMRT reached better dose sparing for bladder, rectum, and small bowel than did VMAT. On the other hand, Riou et al. [27] indicated a clinically and statistically significant reduction in doses delivered to the bladder, rectum, and small bowel when using VMAT in simultaneous integrated boost plans. However, this study used the single-phase SIB for dose calculation rather than two phases like our study and the Yoo study. Also, [14] reported grade II GI and GU toxicity of 31% and 44% respectively with total dose of 79.8
Gy/42 fractions. Also, Deville et al., [28] reported 50% grade II toxicity for both GI and GT. On the other hand, Ishii et al., [29] [31] . Therefore, the acceptably low incidence of acute toxicity in the current study might contribute to decreasing the late side effects in further follow-up. In the current study, there was no correlation between the acute toxicity and the dosimetric parameters. The same finding was also observed by other investigators [29] [32] and [33] . This lack of correlation between toxicity and dosimetric variables could be due to the low dosimetric parameters and low frequencies of the severe acute toxicities. In this study, daily image guidance with OBI KV and biweekly CBCT was practiced in all patients. Ferjani et al. [34] demonstrated that pelvic SIB-IMRT for both PLNs and the prostate, with a planning margin to the prostate of 6 -8 mm and a planning margin of 5 mm to the PLN, would result in good aligning to the prostate soft tissue on daily CBCT, but aligning to the pelvic bone would result in underdosing to the prostate in one-third of fractions. For that reason, we used 7 mm margin for PLNs, 10 mm as PTV margin for the prostate in phase one and 6 mm for boost. Also, all patients were adapted to have comfortably full bladder and rectum evacuated before each radiation treatment session to decrease the chance of prostate mobility.
In the current study, IG was done without fiducial markers (FMs) and image registration was done based on both boney marks and soft tissues. Chung et al. [35] reported 13% of acute GI and GU toxicity based on registration with intraprostatic fiducial markers that allowed for smaller margins and subsequently lower acute toxicity to the bladder and rectum. All patients were given neoadjuvant hormonal therapy for 4 -6 weeks prior to radiation and concomitant with radiation therapy. There is evidence that androgen deprivation has favorable impacts on both local (prostate) disease and distant metastatic disease [36] .
Mercader et al. [37] reported a T-cell infiltration of the prostate induced by ADT and a consequent increase in apoptosis. Furthermore, in an updated analysis of RTOG 94-13 phase III trial, Lawton et al. showed an unexpected interaction between ADT and radiation, which could be due to an immunomodulation in- [5] .
The limitations of our study include the small number of patients in the analysis and the short follow-up period to assess the late toxicity of this technique.
However, the acceptably low incidence of acute toxicity and absence of grade III toxicity would predict a low incidence of chronic toxicity. Furthermore, the role of combined dose escalation and ADT in high risk prostate cancer patients and its effect on overall survival (OS) needs to be assessed in the future by phase III randomized study.
Conclusion
The use of dose escalation in two phases combined with ADT in high risk prostate cancer patient is feasible and associated with acceptable acute GI and GU toxicity. Daily Image guidance is effective to ensure adequate coverage of both LNs and prostate with good sparing of risk organs.
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